DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1751)

Neuropathic Pain | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis in Trigeminal Neuralgia (US)

Neuropathic Pain | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis in Trigeminal Neuralgia (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Trigeminal neuralgia (TGN) is a rare and painful disorder, usually triggered by innocuous stimuli, resulting in paroxysmal neuropathic facial pain in the regions served by the trigeminal nerve. Carbamazepine (Tegretol, generics) is the only therapy formally approved for the treatment of TGN in the United States, but its use is limited by safety and tolerability concerns. Therefore, TGN patients may be managed by a variety of off-label medications along their treatment journey, including oxcarbazepine (Supernus’s Oxtellar XR, generics), other antiepileptics, gabapentin (Neurontin, generics), opioid analgesics, and even neuromuscular blocking agents (Allergan’s Botox). However, a substantial portion of TGN patients are treatment refractory, and better treatment options for these patients are needed.


  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed TGN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed TGN patients?
  • How is carbamazepine integrated into the treatment algorithm, given its safety and tolerability disadvantages?
  • What proportion of TGN patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of TGN patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with TGN?


Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key companies: Pfizer, Allergan

Key drugs:  Carbamazepine/ carbamazepine XR, oxcarbazepine, gabapentin, Lyrica, opioid analgesics, Botox, other antiepileptics

Key analysis provided:

  • Brand use across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis in Trigeminal Neuralgia (US)
    • 2018 Treatment Algorithms: Claims Data Analysis in Trigeminal Neuralgia (November 2018)

Already a Client? Log in to access this report.

  • Pub Date: November 2018
  • Author(s): Natalie Taylor, PhD
  • Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.

Purchase Report

Recent reports:
You may also be interested in: